journal
Journals Therapeutic Advances in Neurol...

Therapeutic Advances in Neurological Disorders

https://read.qxmd.com/read/38585373/cladribine-tablets-after-treatment-with-natalizumab-cladrina-rationale-and-design
#21
JOURNAL ARTICLE
Peter V Sguigna, Rehana Z Hussain, Annette Okai, Kyle M Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve
BACKGROUND: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods. Sequential combination therapy is a plausible alternative approach. Natalizumab is a monoclonal therapeutic antibody that reduces leukocyte access to the central nervous system that is associated with an increased risk of progressive multifocal leukoencephalopathy and disease reactivation after its discontinuation...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38572394/machine-learning-based-prediction-of-stroke-in-emergency-departments
#22
JOURNAL ARTICLE
Vida Abedi, Debdipto Misra, Durgesh Chaudhary, Venkatesh Avula, Clemens M Schirmer, Jiang Li, Ramin Zand
BACKGROUND: Stroke misdiagnosis, associated with poor outcomes, is estimated to occur in 9% of all stroke patients. OBJECTIVES: We hypothesized that machine learning (ML) could assist in the diagnosis of ischemic stroke in emergency departments (EDs). DESIGN: The study was conducted and reported according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines. We performed model development and prospective temporal validation, using data from pre- and post-COVID periods; we also performed a case study on a small cohort of previously misdiagnosed stroke patients...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38566910/exploring-the-association-between-weight-loss-inducing-medications-and-multiple-sclerosis-insights-from-the-fda-adverse-event-reporting-system-database
#23
JOURNAL ARTICLE
Afsaneh Shirani, Anne H Cross, Olaf Stuve
BACKGROUND: Several studies have demonstrated that early childhood and adolescent obesity are risk factors for multiple sclerosis (MS) susceptibility. Obesity is thought to share inflammatory components with MS through overproduction of pro-inflammatory adipokines (e.g., leptin) and reduction of anti-inflammatory adipokines (e.g, adiponectin). Recently, drug repurposing (i.e. identifying new indications for existing drugs) has garnered significant attention. The US Food and Drug Administration Adverse Event Reporting System (FAERS) database serves not only as a resource for mining adverse drug reactions and safety signals but also for identifying inverse associations and potential medication repurposing opportunities...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38560408/treatment-switches-of-disease-modifying-therapies-in-people-with-multiple-sclerosis-long-term-experience-from-the-german-ms-registry
#24
JOURNAL ARTICLE
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C Salmen, Ksenija Schirduan, Tom P A Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K Zettl, Melanie Peters, Clemens Warnke
BACKGROUND: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. OBJECTIVE: To compare switchers and non-switchers, characterize the first DMT switch and identify reasons and predictors for switching the first DMT. METHODS: Data on 2722 PwMS from the German MS Registry were retrospectively analyzed regarding sociodemographic/clinical differences between 1361 switchers (PwMS discontinuing the first DMT) and non-switchers matched according to age, sex, and observation period...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38560407/serum-neurofilament-light-chain-correlations-in-patients-with-a-first-clinical-demyelinating-event-in-the-reflex-study-a-post-hoc-analysis
#25
JOURNAL ARTICLE
Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Mark S Freedman, Andrea Seitzinger, Sanjeev Roy
BACKGROUND: In REFLEX, subcutaneous interferon beta-1a (sc IFN β-1a) delayed the onset of multiple sclerosis (MS) in patients with a first clinical demyelinating event (FCDE). OBJECTIVES: This post hoc analysis aimed to determine whether baseline serum neurofilament light (sNfL) chain can predict conversion to MS and whether correlations exist between baseline sNfL and magnetic resonance imaging (MRI) metrics. METHODS: sNfL was measured for 494 patients who received sc IFN β-1a 44 μg once weekly (qw; n  = 168), three times weekly (tiw; n  = 161), or placebo ( n  = 165) over 24 months...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532803/sex-differences-in-multiple-sclerosis-relapse-presentation-and-outcome-a-retrospective-monocentric-study-of-134-relapse-events
#26
JOURNAL ARTICLE
Pauline Thränhardt, Admirim Veselaj, Christoph Friedli, Franca Wagner, Stefanie Marti, Lara Diem, Helly Hammer, Piotr Radojewski, Roland Wiest, Andrew Chan, Robert Hoepner, Anke Salmen
BACKGROUND: Reporting of sex-specific analyses in multiple sclerosis (MS) is sparse. Disability accrual results from relapses (relapse-associated worsening) and independent thereof (progression independent of relapses). OBJECTIVES: A population of MS patients during relapse treated per standard of care was analyzed for sex differences and short-term relapse outcome (3-6 months) as measured by Expanded Disability Status Scale (EDSS) change. DESIGN: Single-center retrospective study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532802/patisiran-exposure-in-early-pregnancy-a-case-report
#27
Valentin Loser, Thomas Baumgartner, Hélène Legardeur, Alice Panchaud, Marie Théaudin
We describe here the first case of exposure to patisiran treatment, a small interfering RNA molecule, during early pregnancy of a 36-year-old woman with symptomatic hereditary transthyretin-related amyloidosis. There were no major complications during pregnancy and delivery, except for a postpartum hemorrhage due to uterine atony. Vitamin A levels had to be closely monitored during pregnancy, and vitamin A substitution adapted accordingly. There was no sign of minor or major congenital abnormalities of the baby...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38532801/improved-visualization-of-median-ulnar-nerves-and-small-branches-in-the-wrist-and-palm-using-contrast-enhanced-magnetic-resonance-neurography
#28
JOURNAL ARTICLE
Jiamin Kang, Wenjun Wu, Xiangchuang Kong, Yu Su, Dingxi Liu, Chungao Li, Nan Gao, Youzhi Wang, Chuansheng Zheng, Yuxiong Weng, Lixia Wang
BACKGROUND: Magnetic resonance imaging of peripheral nerves in the wrist and palm is challenging due to the small size, tortuous course, complex surrounding tissues, and accompanying blood vessels. The occurrence of carpal palmar lesions leads to edema, swelling, and mass effect, which may further interfere with the display and identification of nerves. OBJECTIVE: To evaluate whether contrast-enhanced magnetic resonance neurography (ceMRN) improves the visualization of the morphology and pathology of the median, ulnar nerves, and their small branches in the wrist and palm...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38525490/comparative-efficacy-of-ofatumumab-versus-oral-therapies-for-relapsing-multiple-sclerosis-patients-using-propensity-score-analyses-and-simulated-treatment-comparisons
#29
JOURNAL ARTICLE
Nicholas Riley, Christopher Drudge, Morag Nelson, Anja Haltner, Michael Barnett, Simon Broadley, Helmut Butzkueven, Pamela McCombe, Anneke Van der Walt, Erin O Y Wong, Martin Merschhemke, Nicholas Adlard, Rob Walker, Imtiaz A Samjoo
BACKGROUND: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as a distinct group of high-efficacy disease-modifying therapies (DMTs) for patients with relapsing multiple sclerosis (RMS). This is counter to the current perception of these therapies by some stakeholders, including payers. OBJECTIVES: A multifaceted indirect treatment comparison (ITC) approach was undertaken to clarify the relative efficacy of mAbs and oral therapies...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38525489/treatment-access-and-satisfaction-on-disease-modifying-therapies-of-neuromyelitis-optica-spectrum-disorder-patients-in-china-a-cross-sectional-survey
#30
JOURNAL ARTICLE
Yue Yu, Mingkang Zhong, Chao Quan, Chunlai Ma
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare and debilitating disease that has become more widely recognized in China. Legislative measures have been implemented by the government to improve treatment access for rare diseases. OBJECTIVES: To investigate the diagnostic journey, treatment status, treatment accessibility, and treatment satisfaction of the NMOSD patients on disease-modifying therapies (DMTs) in China. DESIGN: A patient online survey...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38525488/shifting-from-the-treat-to-target-to-the-early-highly-effective-treatment-approach-in-patients-with-multiple-sclerosis-real-world-evidence-from-germany
#31
JOURNAL ARTICLE
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, Nils-Henning Neß, Maike Hollnagel-Schmitz, Vivien Gerencser, Julia Rustemeier, Markus Eberl, Benjamin Friedrich, Tjalf Ziemssen
BACKGROUND: While evidence highlights the effectiveness of initiating disease-modifying therapy with a high-efficacy medication for multiple sclerosis (MS) patients with poor prognostic factors, it remains unclear whether this approach has been adopted by a broad range of MS providers in Germany yet. OBJECTIVE: To assess the adoption of the early highly effective treatment (EHT) compared to the treat-to-target treatment approach with the option of escalating treatment efficacy over time in Germany based on real-world evidence data...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38525487/clinical-characteristics-and-surgical-outcomes-of-low-grade-epilepsy-associated-brain-tumors
#32
JOURNAL ARTICLE
Suhui Kuang, Shaohui Zhang, Zhiqiang Cui, Ming Ge, Liu Yuan, Jiaqi Wang, Zhirong Wei, Jinshan Xu, Feng Zhai, Shuli Liang
BACKGROUND: Low-grade epilepsy-associated brain tumors (LEATs) are found to be the second most common lesion-related epilepsy. Malignant potential of LEATs is very low and the overall survival is good, so the focus of treatment is focused more on seizure outcome rather than oncological prognosis. OBJECTIVES: This study was conducted to evaluate the risk factors of seizure outcomes after resection in patients with LEATs. DESIGN: A retrospective study...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38495364/disease-modifying-therapy-initiation-patterns-in-multiple-sclerosis-in-three-large-ms-populations
#33
JOURNAL ARTICLE
Alexander Stahmann, Elaine Craig, David Ellenberger, Firas Fneish, Niklas Frahm, Ruth Ann Marrie, Rod Middleton, Richard Nicholas, Jeff Rodgers, Clemens Warnke, Amber Salter
BACKGROUND: Treatment guidelines recommend early disease-modifying therapy (DMT) initiation after diagnosis of multiple sclerosis (MS). Multinational comparative studies that assess time to DMT initiation in MS may allow detection of barriers inherent to healthcare systems to explain potential adverse systematic delays in commencing DMTs. OBJECTIVES: To investigate and compare the time to first DMT and its association with sociodemographic and clinical variables after MS diagnosis in three large MS registries...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38495363/concurrent-acute-sensorimotor-axonal-neuropathy-and-disseminated-encephalitis-associated-with-chlamydia-pneumoniae-in-an-adult-patient-with-anti-mog-and-anti-sulfatide-antibodies-a-case-report
#34
Michail Papantoniou, Grigorios Panagopoulos
Acute disseminated encephalomyelitis and Guillain-Barré syndrome refer to post-infectious or post-vaccination inflammatory demyelinating disorders of central and peripheral nervous system, respectively. We report the case of a 60-year-old male patient presenting with irritability, gait difficulty, asymmetric quadriparesis (mostly in his left extremities), distal sensory loss for pain and temperature in left limbs, and reduced tendon reflexes in his upper limbs and absent in his lower limbs, following an upper respiratory tract infection, 3 weeks earlier...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38476466/the-effects-of-treatment-with-pimavanserin-on-activities-of-daily-living-in-patients-with-parkinson-s-disease-psychosis-a-16-week-single-arm-open-label-study
#35
JOURNAL ARTICLE
Virgilio G H Evidente, Daryl DeKarske, Bruce Coate, Victor Abler
BACKGROUND: More than half of patients with Parkinson's disease will experience psychosis symptoms in the form of hallucinations or delusions at some point over the course of their disease. These symptoms can significantly impact patients' health-related quality of life, cognitive abilities, and activities of daily living (ADLs) and function. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed this sufficiently, in part due to a lack of appropriate scales for comprehensively assessing function...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38455848/know-dbs-patient-perceptions-and-knowledge-of-deep-brain-stimulation-in-parkinson-s-disease
#36
JOURNAL ARTICLE
Meagen Salinas, Umar Yazdani, Austin Oblack, Bradley McDaniels, Nida Ahmed, Bilal Haque, Nader Pouratian, Shilpa Chitnis
INTRODUCTION: Deep brain stimulation (DBS) is an established therapy for Parkinson's disease (PD) that can significantly improve motor symptoms and quality of life. Despite its effectiveness, little is known about patient perceptions of DBS. OBJECTIVES: To evaluate patient perceptions of DBS for PD, focusing on understanding, satisfaction, and factors influencing their outlook. This study aims to enhance patient education and counseling by identifying key determinants of patient perceptions...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38414723/long-term-clinical-outcomes-in-patients-with-multiple-sclerosis-who-are-initiating-disease-modifying-therapy-with-natalizumab-compared-with-bracetd-first-line-therapies
#37
JOURNAL ARTICLE
Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan, Tim Spelman
BACKGROUND: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance. OBJECTIVES: Evaluate long-term clinical outcomes in patients with MS who initiated treatment with either natalizumab or a BRACETD therapy (interferon beta, glatiramer acetate, teriflunomide, or dimethyl fumarate). DESIGN: This retrospective analysis utilized data from MSBase to create a matched population allowing comparison of first-line natalizumab to first-line BRACETD...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38414722/anti-nmda-receptor-encephalitis-and-concurrent-neuroborreliosis-misdiagnosed-for-post-covid-19-syndrome-a-case-report
#38
Tobias Brummer, Johannes Lotz, Christian Dresel, Frank Birklein
We present a case of a 42-year-old woman with paraneoplastic anti-N-Methyl-D-Aspartat (NMDA)-receptor encephalitis and concurrent neuroborreliosis that was initially misdiagnosed as post-COVID-19 syndrome. Clinically, the patient presented with a range of chronic and subacute neuropsychiatric symptoms and recalled a tick bite weeks prior to admission. The patient had undergone psychiatric and complementary medical treatments for 1 year before admission and was initially diagnosed with post-COVID-19 syndrome...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38371384/eomesodermin-expressing-cd4-th-cells-and-association-with-pregnancy-in-multiple-sclerosis
#39
JOURNAL ARTICLE
Simon Faissner, Marielena Bongert, Paulina Trendelenburg, Sandra Thiel, Takashi Yamamura, Kerstin Hellwig, Ralf Gold
BACKGROUND: Pregnancy in patients with multiple sclerosis (MS) is accompanied by a decline of relapse activity with increased risk of relapses 3 months post-partum, for unknown reasons. Eomesodermin+ T-helper cells (Eomes+ Th cells) are known to mediate neuroinflammation and disease progression in MS and are induced by prolactin-secreting cells. OBJECTIVES: Here, investigated immune cell alterations and the pathophysiological role of Eomes+ Th cells for disease activity during pregnancy and post-partum in MS...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38371383/cerebral-pulsatility-in-relation-with-various-imaging-markers-of-cerebral-small-vessel-disease-a-longitudinal-community-based-study
#40
JOURNAL ARTICLE
Weiyi Zhong, Yiwei Xia, Yunqing Ying, Yi Wang, Lumeng Yang, Xiaoniu Liang, Qianhua Zhao, Jianjun Wu, Zonghui Liang, Xiaoxiao Wang, Xin Cheng, Ding Ding, Qiang Dong
BACKGROUND: Cerebral pulsatility is thought to reflect arterial stiffness and downstream microvascular resistance. Although previous studies indicated cerebral pulsatility might closely relate to development of cerebral small vessel disease (SVD), yet evidence remain controversial and longitudinal data are rare. OBJECTIVE: We aimed to explore relationships of cerebral pulsatility with severity and progression of various SVD imaging markers among the community-dwelling elderly...
2024: Therapeutic Advances in Neurological Disorders
journal
journal
42104
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.